Ionis Pharmaceuticals (IONS) Expected to Announce Quarterly Earnings on Wednesday

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Wednesday, April 30th. Analysts expect the company to announce earnings of ($1.07) per share and revenue of $144.31 million for the quarter. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 19th. The company reported ($0.66) EPS for the quarter, topping analysts' consensus estimates of ($1.12) by $0.46. The company had revenue of $227.00 million for the quarter, compared to analyst estimates of $140.97 million. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. The firm's quarterly revenue was down 30.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.12 earnings per share. On average, analysts expect Ionis Pharmaceuticals to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Ionis Pharmaceuticals Stock Performance

NASDAQ:IONS opened at $29.03 on Wednesday. The company has a market capitalization of $4.61 billion, a PE ratio of -9.55 and a beta of 0.29. Ionis Pharmaceuticals has a fifty-two week low of $23.95 and a fifty-two week high of $52.34. The company has a debt-to-equity ratio of 2.12, a quick ratio of 8.82 and a current ratio of 8.47. The company has a 50 day simple moving average of $30.79 and a two-hundred day simple moving average of $34.08.

Analyst Ratings Changes

A number of equities analysts recently weighed in on IONS shares. Redburn Atlantic initiated coverage on shares of Ionis Pharmaceuticals in a research note on Monday, March 31st. They set a "neutral" rating and a $39.00 target price for the company. HC Wainwright began coverage on Ionis Pharmaceuticals in a research note on Monday, April 7th. They issued a "buy" rating and a $45.00 price objective on the stock. BMO Capital Markets decreased their target price on Ionis Pharmaceuticals from $60.00 to $45.00 and set a "market perform" rating for the company in a research note on Thursday, February 20th. Guggenheim reiterated a "buy" rating on shares of Ionis Pharmaceuticals in a report on Thursday, April 3rd. Finally, JPMorgan Chase & Co. cut their price target on Ionis Pharmaceuticals from $47.00 to $45.00 and set a "neutral" rating on the stock in a report on Monday, March 24th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $56.72.

Insider Buying and Selling

In other Ionis Pharmaceuticals news, CEO Brett P. Monia sold 13,242 shares of the company's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $32.45, for a total value of $429,702.90. Following the completion of the transaction, the chief executive officer now owns 219,526 shares in the company, valued at $7,123,618.70. This represents a 5.69 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Patrick R. O'neil sold 1,207 shares of Ionis Pharmaceuticals stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $32.35, for a total value of $39,046.45. Following the sale, the executive vice president now owns 56,245 shares in the company, valued at $1,819,525.75. The trade was a 2.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 63,167 shares of company stock worth $2,010,458. 2.71% of the stock is owned by insiders.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.